The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor

References

Page 1

	Year	Citations
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Y H Hsiang, Robert Hertzberg, Sidney M. Hecht, Journal of Biological Chemistry ChromatinGenome InstabilityDna DamageChromatin RemodelingNatural Sciences	1985	2.3K
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Yaw Huei Hsiang, Leroy F. Liu PubMed Genome InstabilityAnticancer Drug CamptothecinIntracellular TargetMedicineNatural Sciences	1988	844
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts Beppino C. Giovanella, John S. Stehlin, Monroe E. Wall, Science Tumor BiologyGastrointestinal OncologyHuman Colon CancerMedicinePharmacology	1989	645
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors Peter J. Houghton, Pamela J. Cheshire, James D. Hallman, Cancer Chemotherapy and Pharmacology Human TumorsOncologyMedicinePathologyPharmacotherapy	1995	406
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Eric K. Rowinsky, L B Grochow, Carolyn B. Hendricks, Journal of Clinical Oncology	1992	358
WHO Handbook for Reporting Results of Cancer Treatment R.D. Hunter International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine Radiation EffectsRadiation MedicineRadiation TherapyMedicineCancer Management	1980	357
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Franco M. Muggia, Patrick J. Creaven, H.H. Hansen, PubMed Therapeutic Drug MonitoringTranslational MedicinePreclinical StudiesPharmacologyPharmacotherapy	1972	313
Camptothecins: from bench research to hospital wards. M Potmĕsil PubMed MedicineAntibiotic AdjuvantPharmacotherapyBench Research	1994	312
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. T Andoh, Kazuyuki Ishii, Yoshio Suzuki, Proceedings of the National Academy of Sciences ChromatinGenome InstabilityOncogenic AgentNatural SciencesRpmi 8402	1987	288
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Gottlieb Ja, Guarino Am, Call Jb, PubMed Molecular PharmacologyMedicineClinical PharmacologyCamptothecin SodiumPharmacotherapy	1970	250

Page 1